Keywords: Gilead Sciences, Quad, Atripla, Ph III, HIV, Truvada, USA, FDA, AHF, Prevention, PrEP
Gilead's Quad non-inferior to Atripla for HIV; Truvada objections
Article | 08 March 2012
US biotech firm Gilead Sciences (Nasdaq: GILD) yesterday announced full Phase III clinical trial results from pivotal Study 102 demonstrating that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
